The pooling of those trials showed no statistically significant difference in the risk of heart failure between GLP-1 agonists treatment and control (17/7,441 in GLP-1 agonists and 19/4,317 control; OR 0.62, 95 % CI 0.31 to 1.22, I-square = 0 %; risk difference (RD) 19 fewer, 95 % CI 34 fewer to 11 more per 1000 over 5 years) (Fig. 2). This evidence concerns the gene GCG and heart failure.